Global Bacterial Vaginosis Drug Market Insights, Forecast to 2025

Bacterial Vaginosis Drug is used for the treatment of Bacterial Vaginosis (BV), which also known as vaginal bacteriosis or Gardnerella vaginitis, a disease of the vagina caused by excessive bacteria.
The classification of bacterial vaginosis drug includes Rx and OTC, and the proportion of OTC in 2016 is about 72%.

Bacterial vaginosis drug is widely sold in hospital, pharmacy and other field. The most proportion of bacterial vaginosis drug is sold in pharmacy, and the revenue in 2016 is about 423 M USD.

USA region is the largest supplier of bacterial vaginosis drug, with a revenue market share nearly 32% in 2016. Europe is the second largest supplier of Bacterial Vaginosis Drug, enjoying revenue market share nearly 30% in 2016.

USA and Europe are the largest consumption places, with the consumption market share nearly 28% in 2016.

Market competition is intense. Bayer, Pfizer, Sanofi, Piramal, Abbott, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.

The global Bacterial Vaginosis Drug market is valued at 800 million US$ in 2018 and will reach 1030 million US$ by the end of 2025, growing at a CAGR of 3.2% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Bacterial Vaginosis Drug market based on company, product type, end user and key regions.

This report studies the global market size of Bacterial Vaginosis Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Bacterial Vaginosis Drug in these regions.
This research report categorizes the global Bacterial Vaginosis Drug market by top players/brands, region, type and end user. This report also studies the global Bacterial Vaginosis Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Bayer
Pfizer
Sanofi
Piramal
Abbott
Galderma
Mission
Alkem
Xiuzheng
Teva
Perrigo
West-Ward
HPGC
Yunnan Baiyao
Starpharma
Novel
Edenvridge

Market size by Product
Rx
OTC
Market size by End User
Hospital
Pharmacy
Other

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Bacterial Vaginosis Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Bacterial Vaginosis Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Bacterial Vaginosis Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Bacterial Vaginosis Drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Bacterial Vaginosis Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Bacterial Vaginosis Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.